NAD+ Injections: How the Protocol Works and What to Expect

An NAD+ injection puts nicotinamide adenine dinucleotide into tissue or a vein rather than through the gut, because swallowing NAD+ itself does not work well. This page covers what actually happens when you use it: how subcutaneous and intravenous administration differ, why pushing too fast produces the flush everyone warns about, how a protocol is normally structured, and where the human evidence stops. For milligram ranges and syringe arithmetic, the NAD+ injection dosage chart is the page that does that job.

Everything below is research use information. It is not medical advice, it is not a recommendation to start or stop anything, and none of it substitutes for supervision by a qualified clinician who can see your bloodwork and your history.

What an NAD+ Injection Actually Is

Nicotinamide adenine dinucleotide is a coenzyme, present in every cell you have, and it is not a peptide despite where it is sold. It has no amino acid chain. It is a dinucleotide built from an adenine nucleotide and a nicotinamide nucleotide joined through their phosphate groups, which makes it a different class of molecule from BPC-157 or sermorelin entirely. Research chemical vendors list it alongside peptides because their customers buy it alongside peptides, not because the chemistry belongs there.

What it does is carry electrons. NAD+ and its reduced partner NADH shuttle between oxidised and reduced states in the reactions that turn food into ATP, so energy production stalls without an adequate pool of it. It is also consumed rather than merely used by three enzyme families: the sirtuins, the PARPs that repair DNA damage, and CD38. Those enzymes cleave NAD+ and destroy it, so the cell has to keep resynthesising.

The interest in supplementing it comes from one observation: tissue NAD+ concentrations decline with age across several species, and the enzymes that depend on it become less active as that happens. Whether topping the pool back up reverses anything meaningful in humans is the open question, and it is genuinely open.

Why the Injectable Route Exists

Oral NAD+ has a delivery problem. The intact molecule is largely broken down in the digestive tract before it reaches circulation, and the fragments that survive are precursors rather than NAD+ itself. That is why the oral supplement market sells nicotinamide riboside and nicotinamide mononucleotide instead: those are smaller precursors that the body converts back into NAD+ inside cells through the salvage pathway.

Injecting sidesteps that first pass entirely. Whether it also delivers more NAD+ to the tissues that matter is less obvious than it sounds, because circulating NAD+ does not cross cell membranes freely. A reasonable reading of the biochemistry is that injected NAD+ is broken down outside the cell into precursors that then enter and are rebuilt, which would make the route difference smaller than the marketing implies.

Subcutaneous Versus Intravenous

These belong to different settings. The intravenous version is what longevity and wellness clinics sell, typically several hundred milligrams over two to four hours with a nurse adjusting the drip rate whenever the patient reports discomfort. The long duration is not a scheduling preference, it is the point: rate determines whether the session is tolerable.

The subcutaneous version is what people do at home. It uses far smaller amounts per administration, arrives more gradually, and takes minutes rather than an afternoon. The trade is convenience and cost against a lower amount delivered per session. Intramuscular sits in between and shares most of the subcutaneous handling rules.

The IV clinic protocol and the home subcutaneous protocol are not scaled versions of each other, and reading a clinic's milligram figure and reproducing it under the skin in one go is a mistake. The dosage chart covers where the subcutaneous ranges sit.

The Flush, and Why Rate Matters More Than Dose

The reaction NAD+ is known for is distinctive: chest tightness, nausea, cramping in the abdomen, a flushed and warm face, sometimes a feeling of pressure or urgency that people describe as alarming the first time. It is unpleasant, it is common, and it is almost entirely a function of how fast the material arrives rather than how much of it there is.

That single fact is the most useful thing to know about administering NAD+. Slowing or pausing stops the sensation, usually within a minute or two, and resuming more slowly generally lets the same total amount go in without a repeat. Clinics run the drip over hours for exactly this reason, and home subcutaneous users are told to push the plunger over thirty seconds rather than in one motion.

The local sting is a separate complaint. Reconstituted NAD+ is acidic, and the injection is commonly described as burning more than most research compounds do, both during and for a minute afterwards. Letting the vial reach room temperature, keeping the volume small, using a fresh needle and rotating sites all reduce it. The injection technique guide covers rotation and handling.

Reconstitution, Storage and Handling

NAD+ ships lyophilised and is reconstituted with bacteriostatic water like anything else in the category. The powder is usually a pale yellow rather than white, which catches people out, and the solution carries that colour through. Standard practice applies: aim the stream of water at the glass wall rather than directly at the powder, swirl instead of shaking, and wait for it to dissolve rather than agitating it into dissolving.

Stability is where NAD+ differs from a typical peptide. It is less stable in solution than most compounds on this site and sensitive to heat and light, so the working life once reconstituted is shorter. Refrigerate immediately, keep it dark, and treat a solution that has darkened noticeably as a reason to discard rather than push on. The reconstitution guide covers the mechanics and the storage and stability guide covers the temperature side. The bacteriostatic water page explains why the preservative matters for a multi use vial.

How a Protocol Is Usually Structured

Most reported approaches share a shape even where the numbers differ: a loading phase of more frequent dosing over the first few weeks, then maintenance at a lower frequency. Some run continuously at maintenance, others cycle weeks on and weeks off. None of this comes from trial design. It is convention that circulated through clinics and forums and then repeated, which is worth saying plainly rather than dressing up as a protocol.

Where the convention does have defensible logic is in starting small. Tolerance for the flush varies a great deal, first administration reactions are the most common, and there is no way to find out where you sit other than beginning at the bottom of a range.

NAD+ is often run alongside other compounds rather than alone, most commonly in a longevity oriented context. The longevity peptides overview covers how it sits next to the mitochondrial compounds, and MOTS-c and SS-31 are the two most frequently stacked with it because they act on overlapping mitochondrial machinery.

What the Human Research Supports

Less than the marketing does. The mechanistic case is solid and the preclinical work is interesting: NAD+ declines with age in animal models, restoring it improves several markers of mitochondrial function, and the sirtuin and PARP biology gives a coherent reason why that would matter.

The human evidence is thinner in a specific way. Most controlled trial work has been done on the oral precursors rather than on injected NAD+, and those trials show fairly consistently that blood NAD+ metabolites rise with supplementation. What they have been much less able to show is that the rise produces an outcome anyone cares about, in energy, cognition or physical function. Published pharmacokinetic work on intravenous NAD+ is very limited, and studies on subcutaneous self administration in healthy adults are effectively absent.

So the position is this: a real biochemical rationale, a real decline with age, evidence that levels can be raised, and no good evidence yet that raising them by injection produces the outcomes people are buying it for. That is not evidence it does nothing. It is an absence, and a route more invasive than a capsule deserves a clear view of how large that absence is.

Side Effects and Who Should Not Use It

The commonly reported problems are the rate dependent cluster described above, local stinging and redness, transient headache, and occasional light headedness. None appear dose limiting the way a genuine toxicity would be, and most resolve on slowing down or stopping.

The unresolved concerns are longer range rather than acute. There is no long term controlled safety data in healthy adults, so nothing can be said about years of use. The question raised most often is whether pushing NAD+ availability up supports cell populations you would rather not, given that the enzymes it feeds are involved in proliferation and repair. That has not been answered rather than dismissed, and an active or recent malignancy is the clearest reason to keep this in a clinician's hands.

Pregnancy and breastfeeding have no safety data. Anyone on a medication list touching metabolism or the cardiovascular system belongs in a supervised conversation. And the risk that has nothing to do with the molecule applies here as much as anywhere: research grade material carries no assurance of identity, purity or sterility, and how to spot a fake vendor is the more useful safety read than any dose table. The general safety page makes the same case at the category level.

Where People Go Wrong

Pushing it in fast

This is the single most common mistake and it is the one with the most unpleasant result. The flush is rate driven. Thirty seconds of patience removes most of it.

Copying a clinic IV figure into a syringe

An amount designed to arrive slowly over three hours through a vein is not an amount to deliver under the skin in one administration. The routes are not interchangeable and neither are the numbers attached to them.

Leaving it at room temperature

NAD+ in solution degrades faster than most of what sits in the same fridge. Treating it like a BPC-157 vial that tolerates a few hours on the counter is how a vial quietly stops being worth injecting.

Frequently Asked Questions

What is an NAD+ injection?

An NAD+ injection delivers nicotinamide adenine dinucleotide, a coenzyme every cell already uses for energy metabolism and DNA repair, directly into tissue or a vein instead of through the gut. It is sold on research peptide sites and is grouped with peptides commercially, but chemically it is a dinucleotide rather than a peptide, so it has no amino acid chain at all. The injectable route exists because oral NAD+ itself is broken down before it reaches circulation intact.

How long does an NAD+ injection take to work?

Nothing about the timing is well characterised in controlled human work. What users report is a same day change in perceived energy or mental clarity after the first few subcutaneous doses, and a more settled effect after two to four weeks of regular dosing. Those reports are uncontrolled and NAD+ sits in a category where expectation drives a large part of the reported effect, so the honest answer is that the timeline is anecdotal rather than measured.

Does an NAD+ injection hurt?

A subcutaneous NAD+ injection is commonly described as stinging more than most research compounds do, both going in and for a minute or two afterwards. The low pH of reconstituted NAD+ is the usual explanation. Injecting slowly, using a small volume, letting the material reach room temperature first, and rotating sites all reduce it. Intravenous NAD+ produces a different and more systemic sensation rather than local pain.

What is the NAD+ flush and how do you avoid it?

Pushed in quickly, NAD+ produces a recognisable cluster of chest tightness, nausea, abdominal cramping, a flushed face and a feeling of pressure. It is rate dependent rather than dose dependent, which is why clinic IV protocols run over hours rather than minutes and why subcutaneous users are told to push the plunger slowly. Slowing down or pausing is the standard response, and the sensation typically settles within a minute or two.

Is injecting NAD+ better than taking NMN or NR?

It bypasses a digestion problem, which is a real advantage, but better is not established. NMN and NR are oral precursors with the stronger controlled trial record, and several of those trials show measurable rises in blood NAD+ metabolites. Injected NAD+ has far less published human evidence behind it despite being the more invasive route. Anyone choosing the injection is trading a better evidence base for a delivery route that avoids first pass metabolism.

Is NAD+ injection safe?

There is no long term controlled safety data in healthy adults, so safe cannot be stated as a finding. The reported problems are mostly infusion rate effects that resolve on slowing down, plus injection site irritation. The larger practical risk with research grade material is the supply chain: identity, purity and sterility are not guaranteed by a vial label, and a contaminated or mislabelled vial creates problems that careful dosing does not prevent.